Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome

Autor: Yandong Shen, Luke Coyle, Ian Kerridge, William Stevenson, Christopher Arthur, Naomi McKinlay, Keith Fay, Christopher Ward, Matthew Greenwood, Oliver Giles Best, Ann Solterbeck, Alexander Guminski, Stephen Shumack, Stephen P. Mulligan

Publikováno v: eJHaem, Vol 3, Iss 1, Pp 129-138 (2022)

Abstract Chronic lymphocytic leukaemia (CLL) is invariably accompanied by some degree of immune failure, and CLL patients have a high rate of second primary malignancy (SPM) compared to the general population. We comprehensively documented the incide

Externí odkaz: https://doaj.org/article/bfe51b01464c452490529972a47017e0

Metastatic squamous cell carcinoma in chronic lymphocytic leukaemia in a haematology–dermatology multidisciplinary clinic

Autor: Belinda Lai, Yandong Shen, Alexander Guminski, Stephen Shumack, Stephen P. Mulligan

Publikováno v: Australasian Journal of Dermatology. 64:291-295

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::270dd809c261edd077732b39db7e77ee
https://doi.org/10.1111/ajd.13994

Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia

Autor: Stephen P. Mulligan, Stephen Opat, Paula Marlton, Bryone Kuss, Poppy Gerungan, Andrea Puig, Marija McGeachie, Constantine S. Tam

Publikováno v: British Journal of Haematology. 198:790-793

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c6da38e9f2d85b714b643326186ad3
https://doi.org/10.1111/bjh.18306

BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib

Autor: Silvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström, Antonella Capasso, Tatjana Pandzic, Simone Weström, Hassan Foroughi-Asl, Aron Skaftason, Anna Gellerbring, Anna Lyander, Francesca Gandini, Gianluca Gaidano, Livio Trentin, Lisa Bonello, Gianluigi Reda, Csaba Bödör, Niki Stavroyianni, Constantine S. Tam, Roberto Marasca, Francesco Forconi, Panayiotis Panayiotidis, Ingo Ringshausen, Ozren Jaksic, Anna Maria Frustaci, Sunil Iyengar, Marta Coscia, Stephen P. Mulligan, Loïc Ysebaert, Vladimir Strugov, Carolina Pavlovsky, Renata Walewska, Anders Österborg, Diego Cortese, Pamela Ranghetti, Panagiotis Baliakas, Kostas Stamatopoulos, Lydia Scarfò, Richard Rosenquist, Paolo Ghia

Publikováno v: Blood Advances

Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet clinical need. Though BTK and PLCG2 mutations are associated with ibrutinib resistance, their frequency and relevance to progression are not fully understoo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad2c7ae912b770d9360cb931fa52e0de
https://hdl.handle.net/2318/1888045

Real-world evidence on therapeutic strategies and treatment-sequencing in patients with chronic lymphocytic leukemia: an international study of ERIC, the European research initiative on CLL [Abstract]

Autor: Luana Schiattone, Michel van Gelder, Jana Zuchnická, Viola Maria Popov, Rosa Collado, Candida Vitale, Marta Coscia, Gloria Iacoboni, Marta Morawska, Amy Christian, Darko Antic, Vojin Vukovic, Jorge Labrador, Elżbieta Kalicińska, Marek Trněný, Anna Puiggros, Biljana Mihaljevic, Gian Matteo Rigolin, Ioannis Kotsianidis, Dimitra Chammou, Francesca Bacchiarri, Alberto Fresa, Niki Stavroyianni, Sara Galimberti, Alicia Enrico, Lydia Scarfò, David Donaldson, Jacopo Olivieri, Cheyenne Pierie, Irina Panovska, Tamar Tadmor, Maria Papaioannou, Kostas Stamatopoulos, Christos Demosthenous, Mohamed A. Yassin, Olga Kalashnikova, Fatih Demirkan, Yair Herishanu, Livio Trentin, Theodoros P. Vassilakopoulos, Volkan Karakuş, Alessandro Gozzetti, Almudena Navarro-Bailón, Maya Koren-Michowitz, Carlota Mayor-Bastida, Eric Tse, Šárka Pospíšilová, Lucrecia Yáñez, Georgios Karakatsoulis, Roberta Murru, Martin Spacek, Rocío García-Serra, Susanne R. Janssen, Robert J. Kreitman, Michael Doubek, Valerio Guarente, Eugene Nikitin, Uttam Kumar Nath, Anastasia Chatzidimitriou, Iliana Konstantinou, Arnon P. Kater, Ivana Milosevic, Annett Schiwitza, Martin Simkovic, Romain Guièze, Zhenshu Xu, Andrea Visentin, Stanislava Maslejova, Rosa Ruchlemer, Ömür Gökmen Sevindik, Gimena Dos Santos, Alberto Lopez-Garcia, Thomas Chatzikonstantinou, Francesc Bosch Albareda, Miguel Alcoceba, E. Minga, Eleftheria Hatzimichael, Elisa Albi, Lukas Smolej, Gianluca Gaidano, Rainer Claus, Antonio Cuneo, Kamel Laribi, Ramona Cassin, Michalis Iskas, Jana Kotašková, Panayiotis Panayiotidis, Tomas Papajik, Ozren Jakšić, Fatima Miras, Paolo Ghia, Maria Efstathopoulou, Luca Inchiappa, Bonnie Kho, Marcos Daniel De Deus Santos, Barbara Dreta, Constantine S. Tam, George Vrachiolias, Münci Yağcı, Blanca Espinet, B V Biderman, Stephen P. Mulligan, Zadie Davis, Svetlana Smirnova, David Oscier, Juan Marquet Palomanes, Liat Tourjeman, Sofia Chatzileontiadou, Maria Dimou, Riccardo Moia, Isabel González-Gascón y Marín, Anne Calleja, Kristina Tomic, Ilana Levy, Mehreen Ali Khan, Gerasimos Pangalis, Sean Harrop, Thérèse Aurran, Paolo Sportoletti, Dina Sameh Soliman, Shaimaa El-Ashwah, Maria K. Angelopoulou, Gianluigi Reda, Fatiha Merabet, Yandong Shen, Mark Catherwood, Luca Laurenti, Thomas Longval, Deepesh Lad

The use of novel small molecule inhibitors alone or in combination with anti-CD20 monoclonal antibodies for chronic lymphocytic leukemia (CLL) has raised a number of questions on efficacy, tolerability, long-term treatment adherence in patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7a9f4cccd98d74d74691a8db760f3b4
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/98560